Clinical features of chronic hepatitis B in the presence of metabolic syndrome and insulin resistance

被引:0
作者
Tkachenko, L. I. [1 ]
Maleev, V. V. [2 ]
机构
[1] Stavropol State Med Univ, Minist Hlth Russia, Moscow, Russia
[2] Cent Res Inst Epidemiol, Fed Serv Consumer Protect & Welf Rights, Moscow, Russia
关键词
chronic viral hepatitis B; metabolic syndrome; liver fibrosis; hepatic steatosis; insulin resistance; HEPATOCELLULAR-CARCINOMA; STEATOSIS; RISK; CIRRHOSIS; DISEASE; LEVEL;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To assess the relationship of different components of metabolic syndrome (MS), viral load, and HBeAg status to the risk for cirrhosis of the liver in patients with chronic hepatitis B (CHB). Subjects and methods. Fifty-three patients with CHB were examined according to the conventional criteria for patients with chronic hepatitis (the 2012 EASL guidelines). Analysis is made in relation to the degree of liver fibrosis (LF), the presence of MS, abdominal obesity, and insulin resistance (IR). Results. MS was detected in 22.6% of the patients with CHB. The duration of the latter in MS was noted to be longer; the patients with MS were accordingly older than those without MS. The patients of this category were significantly more frequently observed to have type 2 diabetes mellitus (DM2), and IR, hepatic steatosis, and >3 METAVIR scores for LF, and elevated activity of hepatic enzymes (alanine aminotransferase, aspartate aminotransferase). Marked LF was associated with a high viral load, obesity, DM2, patient age, and MS. The patients with MS showed a higher activity of hepatic enzymes than those with abdominal obesity without MS. Conclusion. The percentage of CHB patients with MS increases with disease duration and patient age. High viral load, disease duration, MS, obesity, and DM2 are associated with score >3 METAVIR scores for significant LF.
引用
收藏
页码:18 / 22
页数:5
相关论文
共 19 条
  • [1] Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    Adinolfi, LE
    Gambardella, M
    Andreana, A
    Tripodi, MF
    Utili, R
    Ruggiero, G
    [J]. HEPATOLOGY, 2001, 33 (06) : 1358 - 1364
  • [2] [Антонова Т.В. Antonova T.V.], 2011, [Журнал инфектологии, Zhurnal infektologii], V3, P91
  • [3] Castera L, 2006, Minerva Gastroenterol Dietol, V52, P125
  • [4] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chen, CJ
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Lu, SN
    Huang, GT
    Iloeje, UH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01): : 65 - 73
  • [5] Chen G, 2005, J HEPATOL, V42, P173
  • [6] Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection
    Cindoruk, Mehmet
    Karakan, Tarkan
    Unal, Selahattin
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (05) : 513 - 517
  • [7] Fattovich Giovanna, 2003, Journal of Hepatology, V39, pS50
  • [8] FEDOROV IG, 2004, CONSILIUM MEDICUM, V6, P401
  • [9] Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    Iloeje, UH
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Chen, CJ
    [J]. GASTROENTEROLOGY, 2006, 130 (03) : 678 - 686
  • [10] Kao JH, 2000, INFEC DIS S, P313